Noradrenergic Drug Market - Top Companies and Manufacturers

  • Report ID: 3817
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Companies Dominating the Noradrenergic Drug Landscape

    • Baxter International, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • Novartis AG
    • Bayer AG
    • Sanofi-aventis Groupe
    • Abbott Laboratories
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Siemens Healthcare GmbH
    • Pfizer Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • Baxter International, Inc. introduced premix Norepinephrine Bitartrate in 5% Dextrose Injection, which can be can be kept in automated dispensing cabinets at the point-of-care and has a shelf life of up to 21 months in the refrigerator or up to 90 days at room temperature in overwrap. Further, it is used to treat individuals with acute or emergent hypotension

  • Sanofi-aventis Groupe acquired Provention Bio, Inc., to add TZIELD, the first disease-modifying therapy for the postponement of Stage 3 type 1 diabetes, to the portfolio. Further, the drug TZIELD (teplizumab-mzwv) can be used to postpone the onset of Stage 3 type 1 diabetes (T1D) in adults and children with Stage 2 T1D who are at least 8 years old.

 

 


Author Credits:  Radhika Pawar


  • Report ID: 3817
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of noradrenergic drug is assessed at USD 16.97 Billion.

The noradrenergic drug market size was valued at USD 16.55 Billion in 2023 and is expected to reach USD 23.7 Billion by the end of 2036, expanding at around 2.8% CAGR during the forecast period i.e., between 2024-2036. Growing prevalence of autism, and surging incidences of hypertension are the major factors driving the market growth.

Asia Pacific is likely to dominate majority industry share by 2036, attributed to increasing popularity of antidepressants among the adult population in the region.

Baxter International, Inc., Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, Pfizer Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample